Apogee Therapeutics Inc. (APGE) is all set to be acquired by AbbVie (ABBV) for $135.11 per share in cash, equivalent to a total equity value of approximately $10.9 billion.
Apogee's lead asset, Zumilokibart (APG777), is a late-stage, half-life-extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis. Its pipeline also includes combinations of its novel antibodies and APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), which is being developed in asthma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com